Abilify Off-Label Marketing Case Settled For $4M

Law360, New York (March 27, 2008, 12:00 AM EDT) -- The U.S. subsidiary of Japanese pharmaceutical company Otsuka Pharmaceutical Co. Ltd. has agreed to pay $4 million to settle off-label marketing allegations brought by the U.S. Department of Justice.

The DOJ said Thursday that Otsuka American Pharmaceutical Inc. had agreed to the settlement, putting to rest claims that the company marketed its anti-psychotic drug Abilify for off-label uses by targeting child psychiatrists and nursing homes.

The settlement comes six months after Bristol-Myers Squibb Co. entered into an agreement with the government concerning similar allegations regarding its...
To view the full article, register now.